Novartis AG (NVS) stock
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.32−2.94 (-1.80%)
Close on Nov 11, 2026Market cap $305.92BP/E 22.4Yield –
Novartis EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Novartis's EV/EBITDA was 17.7× on Nov 10, 2026, against 17.8× a year earlier. Over the last 5 years it ranged from 14.6× to 27.4×, with a median of 19.2×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 10, 2026 | 17.7× | −1.2 |
| 2025 | Dec 31, 2025 | 18.8× | −1.2 |
| 2024 | Dec 31, 2024 | 20.0× | −6.5 |
| 2023 | Dec 29, 2023 | 26.6× | +6.5 |
| 2022 | Dec 30, 2022 | 20.0× | +0.7 |
| 2021 | Dec 31, 2021 | 19.3× | −4.2 |
| 2020 | Dec 31, 2020 | 23.5× | −1.8 |
| 2019 | Dec 31, 2019 | 25.2× | +3.8 |
| 2018 | Dec 31, 2018 | 21.5× | −1.9 |
| 2017 | Dec 29, 2017 | 23.4× | +4.6 |
| 2016 | Dec 30, 2016 | 18.7× | – |
See a number that looks wrong?